Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Columbia Laboratories, a specialty pharmaceutical company, has raised $750,000 through the sale of 451,807 shares of its common stock at a price of $1.66 per share to Numoda, a provider of improved trial-performance metrics solutions in enrollment, logistics, monitoring and financial efficiencies for life sciences companies.
Subscribe to our email newsletter
Numoda is currently managing Columbia’s ongoing Pregnant study of Prochieve 8% (progesterone gel) to reduce the risk of preterm birth in women with a short cervix at mid-pregnancy.
Robert Mills, Columbia’s president and CEO, said: “We are pleased to receive this support and vote of confidence in our company. We welcome the interest and investment by Numoda in Columbia’s future.”
Mary Schaheen, Numoda’s CEO, said: “If the Pregnant study is successful, it could lead to improved care for a large number of women at risk for preterm birth and better outcomes for their babies. Numoda is excited to participate in the study and in this investment.”